Tags · Evidence
risk of bias
Structured appraisal of internal validity.
Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · randomised trial · meta-analysis
83 topics · page 2 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] Confounding by indication, explained with a concrete example
Confounding by indication, explained with a concrete example Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
|
+103 | 116 | 22k | 5mo |
|
Measurement error in a self-reported exposure
Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before…
|
+117 | 129 | 45k | 5mo |
|
Heterogeneity as information rather than as a nuisance
Posting this under the heading it deserves: Heterogeneity as information rather than as a nuisance Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
|
+88 | 95 | 1.2k | 6mo |
|
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+7 | 11 | 33k | 7mo |
|
Selection into a registry and what it does to the estimate
Selection into a registry and what it does to the estimate — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
2 | 55k | 7mo | |
|
[2026 update] Conference abstracts as evidence: the weakest common citation
Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-4 ( JAMA , 2024) and finding…
|
2 | 48k | 7mo | |
|
Tracking a preprint to publication: a worked example
Tracking a preprint to publication: a worked example Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…
|
+133 | 147 | 15k | 7mo |
|
Pooling trials with different estimands — what changed since
Pooling trials with different estimands — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURPASS-4 ( Lancet , 2021) and finding…
|
+57 | 64 | 12k | 7mo |
|
What pooling buys you and what it destroys
The question in the title: What pooling buys you and what it destroys I will give what I have already checked below so nobody repeats it. Comparing SURMOUNT-2 ( Lancet , 2023) with LEADER ( N Engl J Med ,…
|
+74 | 83 | 6.6k | 8mo |
|
A preprint whose numbers changed substantially at publication — what changed since
On the subject in the title: A preprint whose numbers changed substantially at publication — what changed since Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it…
|
+3 | 7 | 125 | 8mo |
|
Journal club: how we handle discontinuation in obesity trials — what changed since
Journal club: how we handle discontinuation in obesity trials — what changed since — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it…
|
+14 | 18 | 35k | 8mo |
|
Critiquing an observational claim about a class effect — one year on
Critiquing an observational claim about a class effect — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…
|
+5 | 9 | 3.2k | 8mo |
|
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
|
+81 | 90 | 54k | 9mo |
|
Journal club: indirect comparison between two programmes, defended and attacked — one year on
Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N…
|
+45 | 50 | 3k | 9mo |
|
Conference abstracts as evidence: the weakest common citation
On the subject in the title: Conference abstracts as evidence: the weakest common citation Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
+1 | 5 | 2k | 9mo |
|
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with STEP 4 ( JAMA , 2021) and…
|
+11 | 15 | 4k | 10mo |
|
Reverse causation in a cohort study of weight and outcome — a second dataset
Reverse causation in a cohort study of weight and outcome — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
|
+112 | 131 | 1.5k | 10mo |
|
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question
Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…
|
+80 | 91 | 10k | 11mo |
|
When a preprint is the best available evidence and we say so
When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…
|
+148 | 160 | 31k | 11mo |
|
Journal club: STEP-HFpEF and symptom endpoints
Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding…
|
+18 | 22 | 2.5k | 11mo |
|
Criticising the method without criticising the authors — one year on
On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…
|
+16 | 20 | 61k | 11mo |
|
Immortal time bias in a claims-database study
Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+29 | 34 | 28k | 11mo |
|
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…
|
+50 | 54 | 1.4k | 11mo |
|
[2026 update] Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with…
|
+105 | 118 | 18k | 11mo |
|
Journal club: SURMOUNT-1, read without the press release
Journal club: SURMOUNT-1, read without the press release Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…
|
+139 | 157 | 66k | 12mo |
|
Random versus fixed effects: choosing rather than defaulting
Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before posting;…
|
+16 | 20 | 22k | 13mo |
|
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset
Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with FLOW…
|
+58 | 64 | 17k | 13mo |
|
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
+61 | 65 | 2k | 13mo |
|
Individual participant data versus aggregate data
Posting this under the heading it deserves: Individual participant data versus aggregate data Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
|
+30 | 34 | 64k | 14mo |
|
When a preprint is the best available evidence and we say so — a second dataset
When a preprint is the best available evidence and we say so — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med ,…
|
+20 | 24 | 36k | 14mo |